https://www.selleckchem.com/pr....oducts/smoothened-ag
ngs suggest that RGDfC-Se@siRNA has promising potential as a therapy for colorectal cancer. Treatment aiming to enhance bone tissue regeneration can benefit from multiple growth factor or small molecule delivery. In the present study, the objective was to evaluate the feasibility of using nanocomposite fibrous scaffold to deliver prostacyclin I2 agonist ONO-1301 in combination with BMP2 for treating critical sized bone defect. For this, ONO-1301 at three different concentrations (1.67 μg, 5 μg, 15 μg) and a fixed dose
Like
Comment
Share
